Atria Wealth Solutions Inc. Boosts Position in GSK plc (NYSE:GSK)

Atria Wealth Solutions Inc. boosted its holdings in shares of GSK plc (NYSE:GSK) by 13.2% in the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 32,018 shares of the pharmaceutical company’s stock after purchasing an additional 3,736 shares during the quarter. Atria Wealth Solutions Inc.’s holdings in GSK were worth $1,188,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently bought and sold shares of GSK. Versant Capital Management Inc raised its position in GSK by 2,816.7% during the 4th quarter. Versant Capital Management Inc now owns 700 shares of the pharmaceutical company’s stock worth $26,000 after buying an additional 676 shares during the last quarter. Larson Financial Group LLC grew its stake in shares of GSK by 271.8% during the 3rd quarter. Larson Financial Group LLC now owns 885 shares of the pharmaceutical company’s stock worth $32,000 after purchasing an additional 647 shares during the period. BKM Wealth Management LLC acquired a new stake in shares of GSK during the 4th quarter worth approximately $32,000. Jones Financial Companies Lllp grew its stake in shares of GSK by 62.2% during the 3rd quarter. Jones Financial Companies Lllp now owns 1,327 shares of the pharmaceutical company’s stock worth $48,000 after purchasing an additional 509 shares during the period. Finally, Princeton Global Asset Management LLC grew its stake in shares of GSK by 54.3% during the 4th quarter. Princeton Global Asset Management LLC now owns 1,515 shares of the pharmaceutical company’s stock worth $56,000 after purchasing an additional 533 shares during the period. 15.74% of the stock is owned by hedge funds and other institutional investors.

GSK Price Performance

GSK stock opened at $42.57 on Thursday. The company’s fifty day moving average price is $41.82 and its 200 day moving average price is $39.06. GSK plc has a 1 year low of $33.33 and a 1 year high of $43.84. The stock has a market capitalization of $88.22 billion, a P/E ratio of 14.14, a P/E/G ratio of 1.46 and a beta of 0.64. The company has a debt-to-equity ratio of 1.19, a quick ratio of 0.62 and a current ratio of 0.88.

GSK (NYSE:GSK) last released its quarterly earnings results on Wednesday, January 31st. The pharmaceutical company reported $0.72 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.76 by ($0.04). GSK had a net margin of 16.24% and a return on equity of 51.45%. The company had revenue of $10 billion during the quarter, compared to analyst estimates of $9.79 billion. As a group, equities research analysts anticipate that GSK plc will post 4.03 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

GSK has been the topic of a number of analyst reports. Citigroup raised shares of GSK from a “neutral” rating to a “buy” rating in a research note on Tuesday, February 13th. Morgan Stanley initiated coverage on shares of GSK in a research note on Tuesday, January 23rd. They set an “equal weight” rating on the stock. Guggenheim raised shares of GSK from a “neutral” rating to a “buy” rating in a research note on Monday, March 4th. Finally, Jefferies Financial Group raised shares of GSK from a “hold” rating to a “buy” rating in a research note on Wednesday, January 3rd. One analyst has rated the stock with a sell rating, one has assigned a hold rating, three have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy”.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.